Erin Boh, MD, PhD, FAAD

Key opinion leaders conclude their discussion on plaque psoriasis by commenting on the potential for research into the genetic origin of disease, possible biomarkers, and treatment options with greater efficacy.

A group of specialists discusses unmet needs in psoriatic disease including physician education about biologics and research about treatment options for pediatric patients, patients with malignancies, and patients who are pregnant.

A panel of experts builds a lively discussion on the evolving treatment landscape in plaque psoriasis and highlights the emergence of IL-23 inhibitors as a new class of biologic agents.

Thought leaders in the management of plaque psoriasis share personal insights into factors to consider when treating patients with IL-23 inhibitors, including when to switch biologic agents.

Erin Boh, MD, PhD, FAAD, guides the panel in a conversation about the phase 3 and long-term extension data from the VOYAGE 1 and VOYAGE 2 clinical trials of guselkumab in patients with moderate to severe plaque psoriasis.

George Han, MD, PhD leads a discussion on the pooled analysis of the phase 3 reSURFACE 1 and reSURFACE 2 clinical trials assessing the 5-year safety and efficacy of tildrakizumab in patients with moderate-to-severe psoriasis.

An expert in the management of plaque psoriasis, Erin Boh, MD, PhD, FAAD, highlights the importance of considering comorbidities, prior treatment, health care cost, and insurance when stratifying patients for treatment with biologics.

A specialist in the treatment of plaque psoriasis reviews the mechanism of action for IL-23 inhibitors and examines the dosing and administration of tildrakizumab, guselkumab, and risankizumab.

A panel of experts provides an overview of factors to consider when selecting therapy for patients with plaque psoriasis, including comorbidities, patient preference, and physician education.

Thought leaders in the management of plaque psoriasis consider the favorable safety profile of biologic agents compared to older therapies and highlight their role in the first-line treatment setting.

Neal Bhatia, MD, and Erin Boh, MD, PhD, FAAD, share key insights into the use of IL-12/23 and IL-17 inhibitors for plaque psoriasis as well as commonly comorbid conditions.

George Han, MD, PhD, guides a discussion on the mechanism of action of TNF-alpha inhibitors used to treat plaque psoriasis.

Key opinion leaders in the management of plaque psoriasis review factors to consider regarding quality of life when treating patients with topical agents, phototherapy, and biologics.

Panelists discuss the importance of assessing disease severity to classify patients, documenting signs and symptoms for diagnosis and insurance authorization purposes, and differentiating plaque psoriasis from common mimickers.

Erin Boh, MD, PhD, FAAD, shares insight into clinical manifestations of plaque psoriasis, and panelists emphasize how disease characteristics may be mistaken for signs and symptoms of commonly comorbid diseases.

An expert dermatologist, George Han, MD, PhD, provides a brief overview of the pathogenesis of plaque psoriasis and reviews some common environmental triggers.